Table 4.
Performance of Xpert Against the Reference Standard of MTBDRplus (Line Probe Assay) for Multidrug>-resistant Tuberculosis Detection
| Xpert RIF Resistant | Total | MDR-TB by LPA | |
|---|---|---|---|
| Positive | Negative | ||
| Results | |||
| Positive | 73 | 45 (a) | 28 (b) |
| Negative | 90 | 0 (c) | 90 (d)a |
| Total | 163 | 45 | 118 |
| Sensitivity, % (95% CI) | … | 100.0 (92.1–100) | |
| Specificity, % (95% CI) | … | 76.3 (71.2–85.6) | |
| Positive-predictive value, % (95% CI) | … | 61.6 (49.5–72.8) | |
| Negative-predictive value, % (95% CI) | … | 100.0 (96.6–100) |
Sensitivity = a/a + c; Specificity = d/b + d; positive-predictive value = a/a + b; negative-predictive value = d/d + c.
aThe 2 invalid isoniazid results by LPA were assumed to be susceptible (ie, did not detect MDR-TB) and included in the denominator for the calculation of specificity.
Abbreviations: CI, confidence interval; LPA, line probe assay; MDR-TB, multidrug-resistant tuberculosis; RIF, rifampicin.